dc.contributor.author | Gleeson, M | |
dc.contributor.author | Peckitt, C | |
dc.contributor.author | Cunningham, D | |
dc.contributor.author | Gibb, A | |
dc.contributor.author | Hawkes, EA | |
dc.contributor.author | Back, M | |
dc.contributor.author | Yasar, B | |
dc.contributor.author | Foley, K | |
dc.contributor.author | Lee, R | |
dc.contributor.author | Dash, J | |
dc.contributor.author | Johnson, H | |
dc.contributor.author | O'Hara, C | |
dc.contributor.author | Wotherspoon, A | |
dc.contributor.author | Attygalle, A | |
dc.contributor.author | Menasce, L | |
dc.contributor.author | Shenjere, P | |
dc.contributor.author | Potter, M | |
dc.contributor.author | Ethell, ME | |
dc.contributor.author | Dearden, C | |
dc.contributor.author | Radford, J | |
dc.contributor.author | Chau, I | |
dc.contributor.author | Linton, K | |
dc.date.accessioned | 2017-11-22T16:05:08Z | |
dc.date.issued | 2018-07-03 | |
dc.identifier.citation | Leukemia & lymphoma, 2018, 59 (7), pp. 1586 - 1595 | |
dc.identifier.issn | 1042-8194 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/933 | |
dc.identifier.eissn | 1029-2403 | |
dc.identifier.doi | 10.1080/10428194.2017.1393671 | |
dc.description.abstract | We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS) (n = 50, 32.0%), angioimmunoblastic T-cell lymphoma (AITL) (n = 44, 28.2%), anaplastic large-cell lymphoma (ALCL) ALK negative (n = 23, 14.7%), ALCL ALK positive (n = 16, 10.3%), and other (n = 23, 14.7%). Most patients received CHOP (66.0%) and 13.0% received an autologous hematopoietic progenitor cell transplant (HPCT). With a median follow-up of 63.4 months, 5-year overall survival (OS) and progression-free survival (PFS) was 38.8% and 19.8% respectively. Independent risk factors for inferior OS were age >60 years, International Prognostic Index (IPI) ≥ 2 and lack of complete response to induction. When responding patients were compared by receipt of an autologous HPCT versus not, HPCT was associated with improved PFS (p = .001) and OS (p = .046) and remained significant for PFS in multivariate analysis suggesting a possible therapeutic benefit. | |
dc.format | Print-Electronic | |
dc.format.extent | 1586 - 1595 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | TAYLOR & FRANCIS LTD | |
dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Lymphoma, T-Cell, Peripheral | |
dc.subject | Neoplasm Metastasis | |
dc.subject | Recurrence | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Neoplasm Staging | |
dc.subject | Prognosis | |
dc.subject | Treatment Outcome | |
dc.subject | Combined Modality Therapy | |
dc.subject | Hematopoietic Stem Cell Transplantation | |
dc.subject | Survival Analysis | |
dc.subject | Follow-Up Studies | |
dc.subject | Adolescent | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Aged, 80 and over | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Young Adult | |
dc.subject | Consolidation Chemotherapy | |
dc.subject | Induction Chemotherapy | |
dc.subject | Biomarkers | |
dc.subject | United Kingdom | |
dc.title | Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. | |
dc.type | Journal Article | |
rioxxterms.funder | The Institute of Cancer Research | |
rioxxterms.identifier.project | Unspecified | |
rioxxterms.versionofrecord | 10.1080/10428194.2017.1393671 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
rioxxterms.licenseref.startdate | 2018-07 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Leukemia & lymphoma | |
pubs.issue | 7 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 59 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Medicine (RMH Smith Cunningham) | |
dc.contributor.icrauthor | Yasar, Binnaz | |